Acute Lung Injury & Severe Asthma

Acute Lung Injury & Severe Asthma

Potential to Reverse Acute Lung Injury

Severe asthma, a rare subset of asthma, is characterized by frequent hospitalizations, low Th-2 levels, and/or high neutrophil infiltration. This small but well-defined patient population does not benefit from existing therapies.

The dual-targeting mechanism of RLS-0071, ReAlta’s lead compound, is well suited for treating this rare disease, and potentially many related pulmonary disorders that all have a high unmet medical need.

RLS-0071 has demonstrated powerful and rapid inhibition of neutrophils in a preclinical model of Acute Lung Injury. In a preclinical model, rats treated with RLS-0071 after the injury had an 85% reduction in lung injury damage compared to the non-treated group. Additionally, in similar models, a single IV injection of RLS-0071 significantly reduced levels of pro-inflammatory cytokines and chemokines.

 

 

These findings, as well as other data not shown here, including data from a Phase 1 healthy volunteers’ trial, have given us the confidence to move into clinical evaluation. ReAlta is conducting a Phase 1b mechanism of action study to translate our strong mechanistic preclinical data of Acute Lung Injury into humans. The results of this study will in turn will support further development in the severe asthma indication. More information about this study, which is being conducted in collaboration with the Fraunhofer Institute in Germany, can be found at clinicaltrials.gov under NCT05351671

Preclinical data in our proprietary two-hit animal model shows dramatic decreases of inflammatory cytokines IL-1b, IL-6, IL-17, and TNFa after prophylactic or rescue dosing. RLS-0071 decreases neutrophil infiltration by 85% after single IV injection, preventing lung tissue damage.